TFPI-2 suppresses breast cancer cell proliferation and invasion through regulation of ERK signaling and interaction with actinin-4 and myosin-9

Guangli Wang1,4, Wenhe Huang2,3, Wei Li2, Shaoying Chen2, Weibin Chen1, Yanchun Zhou1, Pei Peng1 & Wei Gu1

TFPI-2 has been recognized as a potent tumor suppressor gene. Low expression of TFPI-2 results in enhanced growth and metastasis of a variety of human tumors. In the present study, we investigated the mechanism responsible for the tumor suppressive effect of TFPI-2. Overexpression of TFPI-2 decreased phosphorylation of ERK1/2 and the translocation of p-ERK1/2 from cytoplasm into the nucleus, and eventually resulted in a reduced cell proliferation. Immunoprecipitation assays identified myosin-9 and actinin-4 as TFPI-2-interacting proteins. Full-length TFPI-2 was required for binding to actinin-4, whereas the N + KD1 regions of TFPI-2 were sufficient to interact with myosin-9. Although overexpression of TFPI-2 or TFPI-2/N + KD1 does not affect the expression of actinin-4 and myosin-9, it inhibits the migration and invasion of human breast cancer cells. Our results suggest that TFPI-2 suppresses cancer cell proliferation and invasion partly through the regulation of the ERK1/2 signaling and through interactions with myosin-9 and actinin-4.

Breast cancer metastasis is one of the leading causes of cancer-related mortality in women worldwide and is the main reason for treatment failure1,2. Tumor metastasis is a multi-step process mediated by a set of factors that promote cell proliferation, motility, reduction of intercellular adhesion, degradation of extracellular matrix (ECM) and other biological events3,4. Invasion of malignant tumors involves ECM-degrading proteases, particularly matrix metalloproteinases (MMPs), which are highly expressed and activated in the tumor microenvironment5. Under physiological conditions, such as tissue remodeling and wound healing, there is a balance between proteolytic degradation and integrity of the ECM. TFPI-2 (human tissue factor pathway inhibitor-2) has been recognized as an important regulatory inhibitor that regulates the activity of serine proteases, and thus mediates ECM degradation and cell invasion6.

TFPI-2, also known as placental protein 5, is a 32-kDa Kunitz-type serine proteinase inhibitor. TFPI-2 contains three Kunitz-type domains (KD) in which the first KD (KD1) of TFPI-2 appears to have all of the structural elements necessary for serine proteinase inhibition7. TFPI-2 is widely expressed in various human tissue cells, such as liver, skeletal, muscle, heart, kidney and pancreas, where the protein is secreted into the extracellular matrix (ECM) to prevent ECM hydrolysis through inhibiting plasmin-mediated activation of MMPs8,9. In addition to secretion, exogenously offered recombinant TFPI-2 can also be rapidly internalized and distributed in both the cytosolic and nuclear fractions of cells to induce caspase-mediated cancer cell apoptosis10,11. Recently, the intracellular function of TFPI-2 has been reported. In the cytoplasm of HT1080 fibrosarcoma cells, the second Kunitz-type domain (KD2) of TFPI-2 has been identified to interact with PSAP (prosaposin), resulting in

1Department of Pathophysiology, The Key Immunopathology Laboratory of Guangdong Province, Shantou University Medical College, Shantou, Guangdong Province, 515041, China. 2Tumor Hospital, Shantou University Medical College, Shantou, Guangdong Province, 515041, China. 3Xiang'an Hospital of Xiamen University, Xiamen, Fujian Province, 361101, China. 4Present address: Department of Prepotency and Genetics, Affiliated Hospital of Guilin Medical University. Guilin, Guangxi, 541001, China. Guangli Wang and Wenhe Huang contributed equally. Correspondence and requests for materials should be addressed to W.G. (email: weigu1@yahoo.com)
repression of the invasive-promoting effects of PSAP. In breast cancer cells, TFPI-2 is able to translocate into the nucleus and suppress the expression of MMP-2 mRNA through the interaction with AP-2a, a transcription factor involved in expression of several genes. These studies suggest that in addition to prevention of the proteolytic degradation of the extracellular matrix, TFPI-2 also can function to suppress cancer cell invasion through the regulation of its binding partners within the cytoplasm and the nucleus.

In the present study, we investigate additional mechanisms by which TFPI-2 mediates the proliferation and invasion of breast cancer cells. We show that overexpression of TFPI-2 results in reduced cell proliferation, which is accompanied by reduced phosphorylation of EGFR/ERK1/2 and decreased translocation of pERK1/2 into the nucleus. We further identify that interactions of TFPI-2 with myosin-9 and actinin-4 inhibit the potential for cell migration and invasion. Our results suggest that TFPI-2 represses cell proliferation through regulation of ERK signaling and that the interactions of TFPI-2 with actinin-4 and myosin-9 contribute to the suppressive effect of TFPI-2 on cell invasion.

**Results**

**TFPI-2 suppresses the proliferation and invasiveness of breast cancer cells.** We have previously reported the role of TFPI-2 in suppressing proliferation and invasiveness of MDA-MB-231 cells. To investigate whether TFPI-2 also functions to inhibit other breast cancer cell lines, we established additional TFPI-2-overexpressing stable cell lines (MCF7/TFPI-2 and T47D/TFPI-2). Control cell lines were generated by infecting previously reported the role of TFPI-2 in suppressing proliferation and invasiveness of MDA-MB-231 cells. To investigate whether TFPI-2 also functions to inhibit other breast cancer cell lines, we established additional TFPI-2-overexpressing stable cell lines (MCF7/TFPI-2 and T47D/TFPI-2). Control cell lines were generated by infecting

**TFPI-2 decreases cell proliferation through suppressing the EGFR-ERK1/2 signaling pathway and nuclear translocation of pERK1/2.** Signaling pathways are often aberrantly activated in human cancers. Among them, ERK signaling is one of the major pathways that contributes to the control of a large number of cellular processes including cell proliferation and metastasis. We hypothesize that a potential mechanism that TFPI-2-mediated breast cancer cell proliferation and invasion could be through the regulation of the EGFR-ERK1/2 signaling pathway. To address this, we examined the effects of TFPI-2 on the expression of the EGFR, extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38). Experiments showed that the protein levels of EGFR, ERK and p38 were basically unchanged in the MDA231 cell lines. However, knockdown of TFPI-2 increased, whereas overexpression of TFPI-2 decreased the levels of phosphorylated EGFR and ERK1/2 proteins (Fig. 2A). Similar reduction of phosphorylated ERK1/2 expression was also observed in MCF7 cells that overexpressed TFPI-2 (Supp. Fig. S1). Moreover, investigation of the pERK1/2 distribution revealed that the relative amount of pERK1/2 was decreased in the nuclear fraction of TFPI-2-expressing cells (Fig. 2B,C). These results indicated that over-expression of TFPI-2 not only decreases the phosphorylation of EGFR and ERK1/2, but also the nuclear translocation of pERK1/2. To assess the contribution of the EGFR-ERK signaling on cell proliferation and invasion, we treated cells with erlotinib, which inhibits the EGFR-ERK signaling pathway and compared its proliferation and invasive potential with TFPI-2 overexpressing and control cells. Although TFPI-2 expression inhibited both cell proliferation and invasion, treatment with erlotinib more evidently decreased the rate of cell proliferation (Fig. 2D,E), and mildly reduced cell invasiveness (Supp. Fig. S2A,B). Immunoblot analysis showed that the phosphorylation of both EGFR and ERK1/2 was reduced after erlotinib treatment (Supp. Fig. S2C). These results indicate that the TFPI-2-mediated EGFR-ERK signaling asserts a greater effect on cell proliferation potential.

**TFPI-2 interacts with α-actinin-4 and myosin-9 in the cytoplasm.** We have previously reported that TFPI-2 widely distributes in both cytoplasm and the nucleus. Translocation of TFPI-2 into the cell nuclei represses transcription of the MMP-2 gene, resulting in reduced invasive ability of breast cancer cells. To investigate the potential function of TFPI-2 in the cytoplasm, we used a HisBind Resin kit to pull down TFPI-2 and its associated proteins from cytosolic extracts of TFPI-2-overexpressing and control MDA231 cells. After precipitation, an aliquot of eluted proteins was used for immunoblotting to detect the precipitated His(6)-tagged TFPI-2 (Fig. 3A, lower). TFPI-2 associated proteins were resolved on 10% SDS-PAGE and followed by Coomassie blue staining (Fig. 3A, upper). In contrast to the control precipitation, two distinct protein bands of ~90 kDa and ~200 kDa were identified in the extracts of TFPI-2 overexpressing cells (Fig. 3A, upper, arrows indicated). Mass spectrometric analysis of the two protein bands revealed that the fast migrating band was actinin-4 (ACTN4, Fig. 3B) and the slower migrating band was myosin-9 (MYH9, Fig. 3C). The coverage rate of the peptide sequences reached 62.0% for actinin-4 and 52.2% for myosin-9, respectively, with 100% matching. Both proteins play important roles in cell migration and invasion. Immunoblot analysis of the two proteins revealed that the fast migrating band was actinin-4 (ACTN4, Fig. 3B) and the slower migrating band was myosin-9 (MYH9, Fig. 3C). The coverage rate of the peptide sequences reached 62.0% for actinin-4 and 52.2% for myosin-9, respectively, with 100% matching. Both proteins play important roles in cell migration and invasion. Immunoblot analysis confirmed that actinin-4 and myosin-9 were present in the pull-down precipitates (Suppl. Fig. 3A). To further verify the physical association of TFPI-2 with the two proteins, we performed reciprocal co-IP experiments using actinin-4 and myosin-9 antibodies. Western blots showed that both actinin-4 and myosin-9 antibodies could precipitate TFPI-2 (Fig. 3D,E). Interestingly, although TFPI-2 was detected in the precipitates of either actinin-4 or myosin-9 antibody, it does not simultaneously complex with the two proteins (Fig. 3,E).

**TFPI-2 colocalizes with ACTN4 and MYH9.** We next performed double immunostaining to investigate the subcellular colocalization of TFPI-2 with myosin-9 or actinin-4. Myosin-9 was observed to be concentrated at the marginal spreading lamellae region of the cells, while actinin-4 was mainly distributed at the edges of cell processes (Fig. 4A,B). In TFPI-2 overexpressing cells, colocalization of TFPI-2 with myosin-9 or actinin-4 at the cell leading edge was increased to about 59% or 52%, compared to 24% or 30% in the control cells (Fig. 4C),
suggesting that overexpression of TFPI-2 increases in vivo interaction of TFPI-2 with myosin-9 and actinin-4. Since TFPI-2 is a Kunitz-type serine proteinase inhibitor, we used western blots to analyze whether interaction with TFPI-2 affects the cellular levels of myosin-9 or actinin-4. As shown by the immunoblots, the protein levels of MYH9 and ACTN4 were not affected when TFPI-2 was either overexpressed or down-regulated (Fig. 4D).
Identification of the regions of TFPI-2 that interact with actinin-4 or myosin-9. Based on the structure of TFPI-2 (Fig. 5A), we used PCR to generate four MBP-fused TFPI-2 truncates, TFPI-2/N+KD1 (amino acids 1–95 of TFPI-2), TFPI-2/ΔKD3 (amino acids 1–158 TFPI-2), TFPI-2/ΔKD1 (amino acids 86–235 of TFPI-2) and TFPI-2/KD3+C (amino acids 154–235 of TFPI-2), and subcloned them into the PCIP2 vector (Fig. 5B). After transfecting the vectors into 293 T cells, we performed western blots using MBP antibody, which indicated that all TFPI-2 truncates were expressed (Fig. 5C). Co-IP experiments revealed that the full length TFPI-2 associates with both myosin-9 and actinin-4 proteins in vivo (Fig. 5D). However, all the four truncates of TFPI-2 were not detected in the precipitates of actinin-4 antibody, indicating that the complete structure of TFPI-2 is required for interaction with actinin-4. In contrast, in addition to the full length TFPI-2, two truncates of TFPI-2 comprising amino acids 1–95 (TFPI2/N+KD1) and 1–158 (TFPI-2/ΔKD3) were detected in the precipitates of myosin-9 antibody (Fig. 5D), suggesting that the N+KD1 region of TFPI-2 is sufficient for interaction with myosin-9.

Interactions of TFPI-2 with MYH9 and ACTN4 reduce cell motility and suppress cell invasion. Since both myosin-9 and actinin-4 play roles in cell migration, we used live-cell imaging to assess the biological consequences of the TFPI-2/myosin-9 and TFPI-2/actinin-4 interactions on cell motility. We infected lentiviral-based expression vectors encoding the MBP-TFPI-2, MBP-TFPI-2/KD3+C or MBP-TFPI-2/N+KD1 truncate into MDA231 and T47D cells and established stable cell lines. Expression of MBP-TFPI-2, MBP-TFPI-2/N+KD1 and MBP-TFPI-2/KD3+C in selected stable cell lines was shown by western blots (Fig. 6A). Cells stably expressing TFPI-2 or TFPI-2 truncates were subjected to motility analysis over a 6-hour period. This approach provided an assessment of the differences in motility between genetically identical cell populations that differed only in their level of TFPI-2 expression. The experiments showed that the average velocity of migration was decreased by ~40% or ~25% in the cells expressing TFPI-2 or TFPI-2/N+KD1, respectively, in contrast to the control cells (Fig. 6B). However, the average velocity was almost unchanged in cells expressing TFPI-2/KD3+C, presumably due to the absence of TFPI-2/KD3+C interaction with myosin-9 or actinin-4. As a result,

Figure 2. TFPI-2 mediates the EGFR-ERK1/2 signaling pathway. (A) Left: representative western blots showing the expressions of EGFR, pEGFR, P38, pP38, pMEK1, ERK1/2, and pERK1/2 proteins in cell lysates of MDA231 cells. β-actin was used as a loading control. Right: relative levels of the proteins were normalized to β-actin. Data for statistical analyses was from three independent experiments. *P < 0.05 as determined by Student’s t-test. (B) Left: representative western blots showing the expressions of ERK1/2, pERK1/2 and TFPI-2 proteins in cytosolic fractions. Quality of cytosolic fractions was verified using anti-α-tubulin antibodies. Right: the intensity of blot bands was assessed by densitometric semi-quantitation and depicted by a bar diagram (mean ± SD). Data for analyses was from three independent experiments. (C) Left: representative western blots showing levels of pERK1/2 and TFPI-2 proteins in the nuclear fraction. Anti-lamin-B antibody was used for verifying the quality of the nuclear fraction. Right: intensity of blot bands was assessed by densitometric semi-quantitation and depicted by a bar diagram (mean ± SD). Data for analyses was from three independent experiments. *P < 0.05 as determined by Student’s t-test. (D) MTT assays were performed to measure the proliferation of MDA231/TFPI-2 and MDA231/con stable cells cultured with erlotinib (2 µm). Results are the average of three independent experiments each carried out in triplicate, ± SD. *P < 0.05 as determined by Student’s t-test. (E) Transwell assays showing the invasive potential of MDA231/TFPI-2 cells and MDA231/con cells treated with erlotinib (2 µm). Data was analyzed from three independent experiments. *P < 0.05, **P < 0.01 as determined by one-way ANOVA followed by Tukey’s multiple comparison tests.
the net path of cell movement was also slower in cells that expressed TFPI-2 or TFPI-2/KD1, in comparison to the control cells and cells expressing TFPI-2/KD3 + C (Fig. 6C). Consistently, knockdown of TFPI-2 expression increased levels of cell motility, possibly resulting from decreased interactions of TFPI-2 with actinin-4 or myosin-9, (Supp. Fig. S4). We then performed in vitro invasion assays using Matrigel-coated transwells in MDA231 cells. The ability of cells to invade through a Matrigel layer towards a chemoattractant in serum is a surrogate indicator of metastasis. Control cells infected with an empty vector were highly invasive (Fig. 6D). However, cells expressing TFPI-2 or TFPI-2/N + KD1 markedly reduced invasive ability by 48% or by 26%. In contrast, cells expressing TFPI-2/KD3 + C exhibited no difference in invasive activity compared with that of control cells (Fig. 6D). Overexpression of TFPI-2 or TFPI-2/N + KD1 also inhibited invasive potential of T47D cells (Suppl. Fig. 3B). Taken together, these results indicate that the expression of TFPI-2 or TFPI-2/N + KD1 alters the cell migration velocity and inhibits cell invasion.

Expression of TFPI-2 mRNA in human breast tumor samples. Using immunohistochemical staining, Xu et al. have reported that the decreased expression of TFPI-2 protein in breast carcinoma tissues is associated with breast cancer progression, recurrence and poor survival outcome. Using immunoblots, we detected that TFPI-2 was expressed in human breast tumors at different levels (Fig. 7A). We then utilized a qRT-PCR approach to examine the relative expression of TFPI-2 mRNA in breast tumor samples (n = 47) and normal breast tissues (n = 8). Results showed that expression of TFPI-2 mRNA was significantly lower in malignant breast tumors than that in normal breast tissues (Fig. 7B), indicating that expression of TFPI-2 could be associated with carcinogenesis and progression of breast tumors. Due to the breast tumour tissues being received as discarded tissue, no analysis of the relationship between TFPI-2 levels and clinical pathologic features was performed.

Methods
Experimental reagents. Mouse anti-TFPI-2 monoclonal antibody (MAB2545) and goat polyclonal antibody (AF2545) against human recombinant TFPI-2 were purchased from R&D systems (Minneapolis, MN, USA). Mouse anti-hTFPI-2 monoclonal antibody (sc-483800) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, USA). Rabbit polyclonal antibody against the C-terminal region of TFPI-2 (CA-1248) was purchased...
from Cell Applications, Inc. (San Diego, California, USA). Mouse antibodies against β-actin, GAPDH, tubulin-α and lamin B were purchased from Bios Inc. (Tokyo, Japan). HRP-conjugated goat anti-rabbit and goat anti-mouse antibodies were purchased from Sigma-Aldrich Chemical Co (St. Louis, MO, USA). Cy3-conjugated donkey anti-rabbit, anti-mouse and anti-goat antibodies, FITC-conjugated donkey anti-goat and anti-rabbit antibodies were purchased from Jackson Immunoresearch Laboratories (West Grove, PA, USA). Restriction endonucleases were purchased from New England Biolabs, Inc. (Ipswich, MA, USA). DNA purification kits were obtained from Qiagen Inc. (Hilden, Germany). Anti-EGFR, anti-phospho-EGFR, anti-ERK1/2, anti-phospho-MEK1/2, anti-P38, and anti-phospho-P38 antibodies were purchased from Cell Signaling, Inc. (MA, USA). Mouse anti-α-actinin-4 antibodies were purchased from Abcam Co. (Cambridge, UK). Rabbit anti-myosin-9 antibody, was obtained from Sigma-Aldrich Chemical Co. (MO, USA).

**Cell lines and cell culture.** Human breast cancer cell lines MDA-MB-231 (MDA231), MCF7, T47D cells and HEK293T cells were purchased from ATCC (USA). TFPI-2 overexpression, TFPI-2 knockdown MDA231 cell lines and control cells were established as previously described13. TFPI-2 overexpression MCF7 and T47D stable cells lines were infection with a pCIP2 vector expressing human His-tagged TFPI-2. Infected cells were cultured and selected with puromycin (2–4 μg/ml) for 2–3 weeks. Expression of TFPI-2 in selected cells was verified by RT-PCR or western blots. A full-length TFPI-2 (1–233 aa) and truncated TFPI-2 cDNAs were PCR amplified, subcloned into pCIP2 vector and transfected HEK293T cells. Expression of TFPI-2 and truncates in transfected cells was verified by western blots. For cell culture, cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml) and streptomycin (100 μg/ml) in a humidified atmosphere containing 5% CO2 at 37°C. When the cells reached 70–80% confluence, they were digested with 0.25% trypsin and passaged. Cells in logarithmic growth phase were collected for experiments.

**Expression of MBP-fused TFPI-2 proteins and in vitro pull-down experiments.** cDNA fragments encoding TFPI-2 and TFPI-2 truncation mutants (N+ KD2, del KDs, KD2+KD3+C and KD3+C) were PCR amplified and were subcloned into the pMalc plasmid (New England Biolabs) at the 3′-terminus of the MBP gene. The pMalc plasmids harboring the MBP-fused TFPI-2 and TFPI-2 truncation mutants were purified and

---

**Figure 4.** TFPI-2 colocalizes with myosin-9 and actin-4. (A) Representative images showing double-immunostaining of TFPI-2 and myosin-9 in TFPI-2 overexpression and control MDA231 cells. The experiments used goat anti-TFPI-2 and murine anti-MYH9 monoclonal antibodies followed by incubation with FITC-conjugated donkey anti-goat IgG and Cy3-conjugated donkey anti-mouse IgG. Scale bars: 10μm. (B) Representative images showing double-immunostaining of TFPI-2 and actinin-4 in MDA231 stable cell lines. The staining used goat anti-TFPI-2 and rabbit anti-actinin-4 antibodies, Scale bars: 10μm. (C) Percentage of cells with colocalized TFPI-2 with myosin-9, and TFPI-2 with actinin-4 in MDA231/TFPI-2 and control cells. An average of 100 cells was examined. *P < 0.05, **P < 0.01 as determined by Student’s t-test. (D) Representative western blots show that TFPI-2 does not affect the expression of actinin-4 and myosin-9 in MDA231 cells.
sequenced. In addition, cDNA fragments of MBP-fused TFPI-2 and TFPI-2 truncations were also subcloned into the PCIP2 lentiviral vector for transfection of HEK293T cells and infection of MDA231 and other breast cancer cells. Cell extracts were prepared from cultured stable cell lines. Pulldown experiments were performed using amyllose beads purchased from New England BioLabs (MA, USA). Briefly, cell extracts were incubated with 30 µl of amyllose beads, washed twice with lysis buffer and centrifuged at 1,000 g. After centrifugation, the amyllose

**Figure 5.** Identification of the regions of TFPI-2 that interact with actinin-4 or myosin-9. (A) A schematic diagram of TFPI-2 showing the organization of conserved domains. The N, or C terminus as well as three KD regions are indicated. The amino acid sequence of each domain is indicated as ‘aa’. (B) Representative drawing of recombinant MBP-tagged full-length TFPI-2, TFPI-2/N+KD1, TFPI-2/ΔKD3, TFPI-2/KD2 + KD3 + C and TFPI-2/ΔKD3 + C used in this study. (C) Representative western blots showing the expression of MBP fused TFPI-2 and TFPI-2 truncates in transfected cells. Lanes 1–5 indicate cell extracts expressing MBP-TFPI-2/N+KD1 (amino acids 1–95 of TFPI-2), MBP-TFPI-2/ΔKD3 (amino acids 1–158 TFPI-2), MBP-TFPI-2/ΔKD1 (amino acids 86–235 of TFPI-2), MBP-TFPI-2/ΔKD3 + C (amino acids 154–235 of TFPI-2) and MBP-TFPI-2, respectively. (D) Pull-down assays and western blots were performed to detect co-precipitated myosin-9 or actinin-4 with MBP-conjugated TFPI-2 or TFPI-2 truncates.
beads were extensively washed and the bound proteins were eluted with 40 µl of 20 mM maltose. Eluted fractions were analyzed by SDS-PAGE and western blotting using antibodies against MBP.

Extracts preparation and western blots. Total cell lysates were prepared as previously described. To prepare nuclear and cytosolic fractions, cells were harvested and washed twice with cold PBS. Five volumes of ice cold cytosolic buffer (10 mM HEPES, pH 7.6, 60 mM KCl, 1 mM EDTA, 0.075% (v/v) NP-40, 1 mM PMSF and 1X protease inhibitor cocktail (Roche diagnostics) were added to the cells, and cells were incubated on ice for 15 min. The cytosolic fraction was collected by centrifugation at 1000 × g for 5 min at 4 °C. The resulting undissolved pellet was washed twice with PBS and resuspended in 2 volumes of cold buffer containing 0.45 M NaCl in 10 mM Hepes (pH 7.4) and 1X protease inhibitor cocktail (Sigma, USA). The suspension was incubated on ice for 15 min and subsequently centrifuged at 18,000 × g for 5 minutes at 4 °C. The resulting supernatant was collected as the nuclear extracts. Subsequently, protein samples were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto 0.45 µm nitrocellulose membranes. Following blocking in 5% fat-free milk for 1 h, the membranes were probed with various primary antibodies (1:500 to 1:1000) overnight at 4 °C. Blots were washed and incubated with respective HRP-conjugated secondary antibodies (1:2000 to 1:5000) for 1 hr. After extensive wash with PBS, the blots were incubated with chemiluminescence reagents (Thermo Scientific, USA). Intensity of blot bands was assessed using Image J software (NIH). The signal intensities of individual protein bands were normalized to β-actin protein [Fig. 2A], tubulin-α [Fig. 2B] or Lamin B [Fig. 2C], respectively.

Cell proliferation assay. Cell proliferation assays were performed as previously described. Briefly, freshly cultured cells were seeded in 96-well plates at 5 × 10^3 cells per well in a final volume of 100 µl. Cell proliferation was determined by a 3-(4,5-dimethylthiazolyl-2-yl)–2,5-diphenyltetrazolium bromide (MTT, Sigma, USA) assay in periods of 2, 24, 48 and 72 hours. Where indicated, erlotinib (2 µM) was present in culture medium to inhibit EGFR/ERK signaling pathway. In each time point, 10 µl (5 mg/ml) of MTT solution was added and incubated for additional 4 hrs at 37 °C. After incubation, 150 µl of DMSO was added and absorbance at 570 nm was measured by a microplate spectrophotometer (BioRad, USA). Each experiment was repeated triplicate, each involving 5 replicates.

Transwell assay. Invasion experiments were performed using 24-well transwell inserts coated with Matrigel (BD Biosciences, USA) at 37 °C for 24 hrs. A total of 2 × 10^4 fresh cells in 200 µl serum-free medium were added to the upper layer of the insert. The lower layer was filled with 500 µl DMEM with 10% FBS as the chemoattractant.
Where indicated, erlotinib (2 µM) was present in the upper chamber. After incubation in a humidified atmosphere containing 5% CO₂ at 37 °C, the Matrigel-coated insert was fixed with methanol and stained with 0.2% crystal violet. Cells on the upper layer of the inserts were wiped out with a cotton swab. The number of stained cells on the lower site of the inserts was counted under the microscope at 200X magnification. 8–10 randomly selected fields were imaged and counted using Image J software. Each experiment was repeated for three times.

Isolation and identification of TFPI-2 associated proteins. Cultured stable cells were lysed in ice-cold lysis buffer [10 mM HEPES pH 7.8, 100 mM NaCl, 10 mM KCl, 0.5% NP-40, with a protease inhibitor mixture]. After centrifugation at 12,000 rpm for 30 min at 4 °C, the supernatants were collected. Pull-down experiments of His-tagged TFPI-2 were performed using a His•Bind Resin kit (Merck Co., NJ, USA) following the manufacturer's instructions. Briefly, cell extracts containing 5 mg of total proteins were incubated with 80 µl of the resins on ice for 4 h with gentle agitation. The resin-coupled His-tagged TFPI-2 and its associated protein were extensively washed, eluted and separated on 4–12% SDS-PAGE (Invitrogen, USA). Protein bands, after Coomassie Blue staining, were excised from the gel and subjected to peptide sequence analysis at Wayne Biotechnologies (Shanghai, China).

Co-immunoprecipitation experiments. Cell extracts were prepared from cultured cell lines. Co-immunoprecipitation experiments were performed using protein A resin (Sigma Aldrich, USA) following the manufacturer's instructions. Briefly, 20 µl of protein A resin was pre-incubated with antibodies against TFPI-2, myosin-9 or actinin-4, respectively, for 30 min. Cell extracts (~1 mg of protein) were added to the mixture and placed on ice for 4 h with gentle agitation. After centrifugation, the resin was washed three times with 500 µl of...
binding buffer, followed by two washes with 500 μl of wash buffer. Bound proteins were eluted with 30 μl of elution buffer. Eluted fractions were analyzed by SDS-PAGE and western blotting using anti-TFPI-2, anti-α-actinin-4 and anti-myosin-9 antibodies.

**Immunofluorescence and microscopy.** Cells for immunofluorescence assays were prepared as previously described. For double staining assays, goat or rabbit anti-TFPI-2 antibody (1:100 to 1:400) with mouse antibody against myosin-9 or actinin-4 (1:400) were used. After washing three times with PBS, cells were incubated with respective Cy3- and FITC-conjugated secondary antibodies for an additional 1 h at room temperature in the dark. Finally, a drop of mounting medium containing DAPI was added and the cells were visualized by a confocal microscope.

**Cell motility assays.** Cell motility assays were performed as previously described. Briefly, cells were cultured in DMEM medium containing 10% FBS. Before imaging, the medium was changed to L-15 (Gibco, USA) containing 10% FBS. Cell motility imaging was performed on an IX71 inverted Olympus microscope using multifield acquisition driven by MetaMorph software. Environmental conditions were controlled for the entirety of motility experiment through the use of a heated chamber. Motility analysis was performed on images at 2-min intervals over a 6-hour period as a way of fully analyzing the total path and net path of cell movement. Tracking was performed in ImageJ using the Manual Tracking and Chemotaxis Tool plug-ins freely available on the ImageJ website. A detailed explanation of motility parameters has been described previously. Centroid coordinates were user determined and later used to calculate the motility statistics presented in the results.

**Total RNA extraction from breast tissues and reverse transcription.** Breast tissue specimens (~50 mg) were homogenized in 1 ml RLT reagent (Qiagen, USA) using a high-speed homogenizer (16,000 rpm). Total RNA was extracted from malignant (n = 47), and normal (n = 8) mammary tissue using an RNeasy Mini Kit (QiAGEN, USA). RNA concentration was quantified using a Nanodrop ND-2000c Spectrophotometer. Collected RNA was used at once or stored at −80 °C. For cDNA synthesis, 1 μg of total RNA was reverse-transcribed using oligo-dT and a Superscript Amplification System (Invitrogen, USA).

**Real-time PCR analysis.** The resulting cDNA was analyzed by Quantitative RT-PCR was carried out in an ABI 7500 Fast real-time PCR system (Applied Biosystems, USA) using SYBR Green PCR Master Mix (Qiagen, USA) according to the manufacturer’s instructions. Cycling conditions for PCR were as follows: 50 °C for 2 min, 95 °C for 15 min followed by 40 cycles of 94 °C for 20 sec and 60 °C for 30 sec. For quantification, values of target genes were normalized to an internal standard control, GAPDH. Relative levels of expression were calculated using the comparative ΔΔ Ct method. For tissue samples, data was expressed relative to the lowest detectable sample in the cohort analysis and expressed as a log10 relative quantity.

**Specimens.** A total of 55 human breast tissue samples, which included 47 breast tumors, were collected from patients who had undergone surgery at the Shantou University Tumor Hospital (Shantou City, Guangdong Province, China) between 2013 and 2014. Normal squamous epithelial specimens were collected from the uteri of patients who had undergone hysterectomy without malignancy. All human breast tumour tissues were received as discarded tissue (excess tumour tissue after enough specimens were collected by the Shantou Tumour Hospital, Pathology Department for diagnostic tests) and did not contain a code derived from individual personal information. The experiments were approved by the Shantou Tumour Hospital (Chairman, Professor Guojun Zhang) and operated according to International Conference on Harmonisation (ICH) / WHO GCP and the applicable laws and regulations.

**Statistical analysis.** Statistical significance was calculated using the Student’s t-test (two-tailed) and a P < 0.05 was considered significant. The statistical difference in more than two groups was evaluated by one-way ANOVA followed by Tukey’s multiple comparison test. All numerical values described represent means ± SD.

**Discussion**

Human TFPI-2, an ECM-associated Kunitz-type serine proteinase inhibitor, is becoming increasingly recognized as a tumor suppressor gene. TFPI-2 has been shown to suppress tumor cell proliferation, invasion and angiogenesis in several malignant tumors, including hepatocellular carcinoma, glioblastomas and lung cancer. In the present study, we identified a correlation between TFPI-2 expression and the ERK signaling pathway that corresponds to the repression of cell proliferation. We further revealed a novel interaction of TFPI-2 with myosin-9 that contributes to inhibition of cell migration and invasion.

In a variety of tissue cells, TFPI-2 has been shown to be important for tumor progression and metastasis. Low expression of TFPI-2 in breast carcinoma tissues is associated with cancer recurrence and poor survival outcome after breast cancer surgery. TFPI-2 is expressed and secreted into the extracellular matrix (ECM) of various human tissues to inhibit plasmin-mediated activation of MMPs and maintains the integrity of the ECM. In addition, the expression of TFPI-2 and VEGF in cervical tumors is negatively correlated and reduced expression of TFPI-2 contributes to angiogenesis and apoptosis of cervical cancer. TFPI-2 has been shown to widely distribute in the cytoplasm and the nucleus. In the cytoplasm of HT1080 fibrosarcoma cells, TFPI-2 interacts with prosaposin (PSAP) and inhibits the invasion-promoting effects of PSAP. In breast cancer cells, interaction of the nuclear-localized TFPI-2 with AP-2α, a transcription factor, negatively regulates the transcription of MMP-2 mRNA and suppresses cell invasion.

Currently, we have identified additional cytoplasmic functions of TFPI-2. We show that TFPI-2-mediated reduction of breast cancer cell proliferation could be through inhibiting phosphorylation of EGFR-ERK1/2 signaling molecules and the nuclear translocation of pERK1/2. Interestingly, although inhibition of the EGFR-ERK phosphorylation significantly suppressed cell proliferation, it only slightly affects cell invasive potential, indicating...
that other mechanisms could be involved in the TFPI-2-regulated reduction of cell invasion. This prompted us to explore other potential mechanisms by which TFPI-2 inhibits invasion and migration of breast cancer cells. Through performing mass spectrometric analyses following TFPI-2 pull-down assays, we identified two potential TFPI-2-associated proteins, actinin-4 and myosin-9. The cytoplasmic interactions of TFPI-2 with actinin-4 and myosin-9 were also confirmed by co-localization assays.

Both myosin-9 and actinin-4 are actin-associated proteins that play crucial roles in cancer cell motility and invasion. Actinin-4 binds to actin filaments to preserve cytoskeletal structure and cell morphology. In non-muscle cells, actinin-4 expression is associated with cell motility and cancer metastasis. During cell movement, actinin-4 concentrates at the leading edge of migrating cells. Overexpression of actinin-4 spreads actin-rich filopodia at the cell leading edge and increases cell motility in colorectal and melanoma cells. Myosin-9, the heavy-chain subunit of non-muscle myosin IIA, is also an actin-binding protein. In MDA231 cells, myosin-9 has been shown to be an important protein for regulating cell spreading and migration. Moreover, a prior study has shown that myosin-9 is necessary for MCF-7 cells to invade. Since the levels of myosin-9 and actinin-4 do not change in either TFPI-2-overexpressing or TFPI-2-silenced cells, we hypothesize that the interactions of TFPI-2 with myosin-9 and actinin-4 may affect the cell migration and invasion. Indeed, increasing TFPI-2 expression markedly decreases random velocity in cell migration, as well as cell invasive ability.

Using co-immunoprecipitation assays, we revealed that TFPI-2 does not simultaneously interact with actinin-4 and myosin-9 in the cytoplasm of breast cancer cells, since neither myosin-9 is detected in the precipitates of actinin-4 antibody, nor actinin-4 in the precipitates of myosin-9 antibody. Further biochemical analysis indicated that full length TFPI-2 is required for interaction with actinin-4. However only the N-terminus + KD1 regions of TFPI-2 are needed for binding to myosin-9 and this interaction resulted in decreased cell motility and invasion. Moreover, the full-length TFPI-2, which interacts with both actinin-4 and myosin-9 shows a stronger repression of cell migration and invasion than the TFPI-2/N + KD1 truncate that only interacts with myosin-9, the mutual interactions of TFPI-2 with myosin-9 or actinin-4 could lead to a combined effect in suppressing migration and invasion of breast cancer cells.

Our experimental results strongly suggest that, in breast cancer cells, TFPI-2 performs multiple functions that rely on its different cellular localizations. Nuclear translocation of TFPI-2 interacts with Ap-2α, leading to the suppression of MMP2 gene expression. Cytoplasmic interactions of TFPI-2 with myosin-9 or actinin-4 affect cell motility and invasion. In addition, TFPI-2 over-expression reduces the phosphorylation of ERK1/2 and the nuclear localization of p-ERK1/2, resulting in suppression of cell proliferation. We hypothesize that the different cellular distributions of TFPI-2 produce multiple functions, possibly via the interactions with different protein partners, leading to the overall inhibition of cell invasion and proliferation.

Consistent with previous report, qRT-PCR results in human breast specimens showed that TFPI-2 transcript levels are particularly low in breast tumor tissues, compared to adjacent normal tissues. This observation would strongly suggest the important function of TFPI-2 in breast tumors and indicate that TFPI-2 may play a suppressive role during breast cancer development.

Conclusions
We show that TFPI-2 modulates the EGFR-ERK signaling pathway to suppress cell proliferation. We also identify actinin-4 and myosin-9 as novel TFPI-2-interacting proteins and show that the TFPI-2/actinin-4 and TFPI-2/myosin-9 interactions lead to the inhibition of cell migration and invasion. The results of the present study provide basic insight for a better understanding of the tumor suppressive role of TFPI-2 in breast cancer cells.

Data Availability
All data generated or analyzed during this study are included in this published article (and its supplementary information files).

References
1. Liubota, R. V., Zotov, A. S., Vereshchako, R. I., Liubota, I. I. & Zaychuk, V. V. Risk Factors of the Invasive Breast Cancer Locoregional Recurrence. BioMed research international 2015, 789646, https://doi.org/10.1155/2015/789646 (2015).
2. Mendes, T. F., Kluskens, L. D. & Rodrigues, L. R. Triple Negative Breast Cancer: Nanosolutions for a Big Challenge. Advanced science, 1500053, https://doi.org/10.1002/advs.201500053 (2015).
3. Tektonidis, M. et al. Identification of intrinsic in vitro cellular mechanisms for glioma invasion. Journal of theoretical biology 287, 131–147, https://doi.org/10.1016/j.jtbi.2011.07.012 (2011).
4. Stamenkovic, I. Extracellular matrix remodelling: the role of matrix metalloproteinases. The Journal of pathology 200, 448–464, https://doi.org/10.1002/path.1400 (2003).
5. Noel, A., Jost, M. & Maquoi, E. Matrix metalloproteinases at cancer tumor-host interface. Seminars in cell & developmental biology 19, 52–60, https://doi.org/10.1016/j.semcdb.2007.05.011 (2008).
6. Chand, H. S., Foster, D. C. & Kisiel, W. Structure, function and biology of tissue factor pathway inhibitor-2. Thrombosis and haemostasis 94, 1122–1130, https://doi.org/10.1160/TH05-07-0509 (2005).
7. Chand, H. S., Schmidt, A. E., Bajaj, S. P. & Kisiel, W. Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2. The Journal of biological chemistry 279, 17500–17507, https://doi.org/10.1074/jbc.M400802200 (2004).
8. Xu, C. et al. Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer. BMC cancer 13, 118, https://doi.org/10.1186/1471-2407-13-118 (2013).
9. Herman, M. P. et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. The Journal of clinical investigation 107, 1117–1126, https://doi.org/10.1172/JCI10403 (2001).
10. Kempaiah, P. & Kisiel, W. Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line. Apoptosis: an international journal on programmed cell death 13, 702–715, https://doi.org/10.1007/s10495-008-0207-8 (2008).
11. Kempaiah, P., Chand, H. S. & Kisiel, W. Human tissue factor pathway inhibitor-2 is internalized by cells and translocated to the nucleus by the importin system. Archives of biochemistry and biophysics 482, 58–65, https://doi.org/10.1016/j.abb.2008.11.028 (2009).
12. Xu, C. et al. The interaction of the second Kunitz-type domain (KD2) of TFPI-2 with a novel interaction partner, prosaposin, mediates the inhibition of the invasion and migration of human fibrosarcoma cells. *The Biochemical journal* **441**, 665–674, https://doi.org/10.1042/Bj20110533 (2012).

13. Wang, G. et al. Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells. *Scientific reports* **7**, 13575, https://doi.org/10.1038/s41598-017-14148-8 (2017).

14. Kim, E. K. & Choi, E. J. Pathological roles of MAPK signaling pathways in human diseases. *Biochimica et biophysica acta* **1802**, 396–405, https://doi.org/10.1016/j.bbadis.2009.12.009 (2010).

15. Li, Z. et al. Erolitinib effectively inhibits Jak2/VE617F activity and polycythemia vera cell growth. *The Journal of biological chemistry* **282**, 3438–3432, https://doi.org/10.1074/jbc.C600277200 (2007).

16. Festuccia, C. et al. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. *The Prostate* **69**, 1529–1537, https://doi.org/10.1002/pros.20995 (2009).

17. Honda, K. et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. *Gastroenterology* **128**, 51–62 (2005).

18. Betapudi, V., Licate, L. S. & Egelhoff, T. T. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. *Cancer research* **66**, 4725–4733, https://doi.org/10.1158/0008-5472.CAN-05-4236 (2006).

19. Derycke, L. et al. The role of non-muscle myosin IIa in aggregation and invasion of human MCF-7 breast cancer cells. The *International journal of developmental biology* **55**, 835–840, https://doi.org/10.1387/ijdb.113336ld (2011).

20. Yoshii, H. et al. Increased expression of alpha-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer. *Oncology reports* **30**, 1073–1080, https://doi.org/10.3892/or.2013.2577 (2013).

21. Song, T. et al. Specific interaction of KIF11 with ZBP1 regulates the transport of beta-actin mRNA and cell motility. *Journal of cell science* **128**, 1001–1010, https://doi.org/10.1242/jcs.161679 (2015).

22. Khan, S. et al. MiR-379 regulates cyclin B1 expression and is decreased in breast cancer. *Plos One* **8**, e68753, https://doi.org/10.1371/journal.pone.0068753. Print 0062013 (2013).

23. Xu, Y. et al. Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma. *Oncology letters* **2**, 779–783, https://doi.org/10.3892/ol.2011.341 (2011).

24. Vaitkiene, P. et al. Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. *FEBS open bio* **3**, 291–301, https://doi.org/10.1002/fob.2013.06.004 (2013).

25. Lavergne, M. et al. Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. *FEBS open bio* **3**, 291–301, https://doi.org/10.1002/fob.2013.06.004 (2013).

26. Gaud, G. et al. TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions. *Journal of cellular and molecular medicine* **15**, 196–208, https://doi.org/10.1111/1582-4934.12099 (2011).

27. Sierko, E., Wojtkiewicz, M. Z. & Kisiel, W. The role of tissue factor pathway inhibitor-2 in cancer biology. *Seminars in thrombosis and hemostasis* **33**, 653–659, https://doi.org/10.1055/s-2007-991532 (2007).

28. Zhang, Q. et al. Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. *Journal of experimental & clinical cancer research: CR* **31**, 1, https://doi.org/10.1186/1756-9966-31-1 (2012).

29. Condeelis, J. & Segall, J. E. Intravital imaging of cell movement in tumours. *Nature reviews. Cancer* **3**, 921–930, https://doi.org/10.1038/nrc1231 (2003).

30. Honda, K. et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. *The Journal of cell biology* **140**, 1383–1393 (1998).

31. Shao, H., Li, S., Watkins, S. C. & Wells, A. alpha-Actinin-4 is required for amoeboïd-type invasiveness of melanoma cells. *The Journal of biological chemistry* **290**, 32717–32728, https://doi.org/10.1074/jbc.M114.579185 (2014).

Acknowledgements
We acknowledge the support of Shantou University Medical College and the Tumor Hospital affiliated of Shantou University Medical College. This work was supported by the National Natural Science Foundation of China (grant number 31071152) to W.G. This work was supported by the National Natural Science Foundation of China (grant number 31071152 and 31171209) to W.G. and National Institutes of Health (NIH) grant GM57071 to R.H.S.

Author Contributions
G.W. and W.L. carried out the molecular and biochemical studies. Y.Z., S.C. and P.P. carried out the cell culture and gene expression assays. W.L., and W.H. participated in human sample collection, biochemistry experiments and statistic analysis. S.C. and W.C. performed cell proliferation, invasion, migration and imaging experiments. W.G. designed the experiments, coordinated studies, and wrote the manuscript. All authors read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-32698-3.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.